eflornithine
information and resources from the National Cancer Institute
eflornithine
A difluoromethylated ornithine compound with antineoplastic activity. Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. eflornithine
A difluoromethylated ornithine compound with antineoplastic activity. Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells.
|
|
|
|
news articles
The Scandal of 'Poor People's Diseases' Mar 28, 2006
New York Times, There is another cure, eflornithine, so effective that it is called the "resurrection drug" – it makes people in comas get up and walk. ...
VANIQA(R) Announces Five-Time Olympic Swimming Medalist, Janet ... Mar 22, 2006
PR Newswire (press release), About VANIQA VANIQA is a prescription topical cream containing 13.9% of eflornithine hydrochloride that is clinically proven to slow down facial hair growth in ...
Barrier Therapeutics Acquires the Canadian Distribution Rights For ... Mar 15, 2006
PharmaLive.com (press release), In addition to Denavir, in Canada Barrier markets Vaniqa ® (eflornithine hydrochloride) Cream 13.9% for slowing the growth of unwanted facial hair in women ...
Barrier Therapeutics to Present Data on Vusion(TM) and Sebazole(TM ... Mar 3, 2006
Market Wire (press release) ...the US and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and markets VANIQA® (eflornithine hydrochloride) Cream ...
Toward The Future Of Cancer Prevention Dec 18, 2005
Science Daily (press release) An international trial in FAP looking at use of Celebrex combined with eflornithine (DFMO), a drug used to treat African sleeping sickness, but which is ...
Toward the Future of Cancer Prevention; Can Most Types of Cancers ... Dec 16, 2005
PR Newswire (press release), ...use of Celebrex as a chemopreventive have been re-opened: * An international trial in FAP looking at use of Celebrex combined with eflornithine (DFMO), a drug ...
Barrier Therapeutics Announces FDA Acceptance of Its New Drug ... Dec 9, 2005
Market Wire (press release) ...the US and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and markets VANIQA®, (eflornithine hydrochloride) Cream ...
|
|
